Every 8-K that BioVie, Inc. (BIVI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BIVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIVI filings page.
BioVie Inc. (BIVI) entered into a sales agreement with A.G.P./Alliance Global Partners to offer and sell, from time to time, shares of its Class A common stock with an aggregate offering price of up to $6,464,341 in an at-the-market offering under its effective Form S-3 shelf registration. The Agent may effect sales on or through The Nasdaq Capital Market or other U.S. trading markets, or in negotiated transactions, using commercially reasonable efforts on terms mutually agreed with BioVie. BioVie will pay the Agent a 3.0% commission on gross proceeds and reimburse specified expenses, and intends to use any net proceeds for general corporate purposes. The program will end upon the earlier of selling all Placement Shares, expiration of the registration statement on the third anniversary of its June 29, 2026 effectiveness, or termination of the agreement by either party; BioVie has no obligation to sell any shares and may suspend or terminate offerings at any time.
BioVie Inc. reported topline results from its Phase 2 SUNRISE-PD trial of oral bezisterim in early-stage Parkinson’s disease patients who had not received carbidopa/levodopa. The multicenter, randomized, double-blind, placebo-controlled study met prespecified endpoints focused on inflammatory biomarkers and exploratory clinical outcomes.
Patients treated with bezisterim showed statistically significant improvements versus placebo on motor and non-motor symptoms measured by MDS-UPDRS Parts I–III and the EPNIC-15 composite, as well as broad shifts in proteomic and neuroinflammatory biomarkers. Biomarker and proteomic endpoints are described as exploratory, and bezisterim’s potential impact on disease progression will require confirmation in future trials, including a potentially pivotal Phase 3 study. Bezisterim was reported to be well tolerated with an adverse event profile comparable to placebo. BioVie plans a conference call on August 12, 2026, to discuss the results.
BioVie Inc. reported that stockholders approved an amendment and restatement of its 2019 Omnibus Equity Incentive Plan, effective November 10, 2025. The revised plan increases the number of shares of common stock authorized for issuance under the plan to 3,100,000 shares.
The plan is intended to help attract, retain, and incentivize employees, directors, and consultants, and to align their interests with stockholders. The full amended plan is incorporated by reference from the company’s September 25, 2025 definitive proxy statement.
BioVie Inc. reported results from its 2025 annual meeting of stockholders. On the September 22, 2025 record date, 7,535,080 shares were outstanding, and 3,417,857 shares were present for quorum. Stockholders elected all six director nominees to one‑year terms; each nominee received over 1.51 million "For" votes, with 1,864,509 broker non‑votes recorded on each director item.
Stockholders ratified EisnerAmper LLP as independent auditor for the fiscal year ending June 30, 2026 with 3,245,049 For, 141,868 Against, and 30,940 Abstain. They also approved an amendment and restatement of the 2019 Omnibus Equity Incentive Plan to increase the number of shares authorized for issuance to 3,100,000 (votes: 1,340,062 For, 207,794 Against, 5,492 Abstain, and 1,864,509 broker non‑votes).
BioVie Inc. completed a registered offering that generated approximately $10.4 million in net proceeds. The company sold 5,620,000 Units and 380,000 Pre-Funded Units, with each Unit containing one share of common stock and one warrant. Units were sold at $2.00 each and Pre-Funded Units at $1.999 each (reflecting a nominal $0.0001 exercise price for the Pre-Funded Warrants).
The Warrants began trading on The Nasdaq Capital Market under the symbol BIVIW on August 8, 2025; each Warrant is immediately exercisable for one share at an exercise price of $2.50 and expires five years from issuance. The Underwriter, ThinkEquity LLC, exercised part of its over-allotment and purchased 667,300 Warrants for nominal additional proceeds; it received 300,000 Underwriter's Warrants exercisable at $2.50 and containing registration and anti-dilution rights. The offering closed August 11, 2025, proceeds are for working capital and general corporate purposes, and the Company and its officers and directors agreed to a three-month lock-up.
On June 26, 2025, BioVie Inc. filed a Form 8-K announcing that its Board of Directors approved a one-for-ten (1:10) reverse stock split of the Company’s Class A common stock, as previously authorized by shareholders at the June 23, 2025 special meeting. The reverse split will become effective at 12:01 a.m. Eastern Time on July 7, 2025. Each block of ten issued and outstanding shares will automatically be reclassified into one share, with the $0.0001 par value unchanged.
The total number of authorized shares of common stock remains the same. All outstanding stock options, restricted stock units, and warrants will be adjusted proportionally: the number of underlying shares will be divided by ten and the corresponding exercise prices increased by the same factor. No fractional shares will be issued; shareholders otherwise entitled to a fraction will receive one whole post-split share.
West Coast Stock Transfer, Inc. will act as exchange agent, and shareholders holding shares in book-entry or “street name” are not required to take any action. Trading will continue on the Nasdaq Capital Market under the symbol “BIVI” on a split-adjusted basis beginning July 7, 2025. The Company’s common stock will adopt a new CUSIP number: 09074F504.
This event is reported under Item 3.03, constituting a material modification to the rights of security holders.
BioVie held a Special Meeting of stockholders on June 23, 2025, with 10,971,031 shares represented out of 18,570,726 outstanding shares of Class A common stock. Two key proposals were voted on:
Proposal 1: Reverse Stock Split Authorization The stockholders approved granting the Board authority to implement a reverse stock split at a ratio between 1-for-5 and 1-for-10, to be executed within one year. The voting results showed:
- For: 8,664,435 shares (79%)
- Against: 2,200,874 shares
- Abstain: 105,722 shares
Proposal 2: Meeting Adjournment Authority Shareholders approved discretionary authority to adjourn the meeting if needed to gather more proxies, with:
- For: 8,788,143 shares (80%)
- Against: 2,033,834 shares
- Abstain: 149,054 shares